Sponsor
Marsha Blackburn
Senator · R-TN
Senator · R-TN
The bill trades meaningful incentives to rebuild U.S. medical manufacturing capacity, improve supply‑chain resilience, and spur cleaner production for a measurable fiscal cost and added complexity that may concentrate benefits among larger firms and require substantial administrative oversight.
Patients, hospitals, military personnel, and veterans could see more reliable domestic supplies of drugs, biologics, devices, and APIs because the credits encourage on‑shore production and stronger supply‑chain resilience.
Domestic medical manufacturers (including small businesses that qualify) can lower their upfront and ongoing costs through credits against manufacturing income and for qualifying equipment and pollution‑control investments, improving the economics of U.S. production.
Incentives for qualifying equipment encourage adoption of advanced manufacturing technologies and faster time‑to‑market, which can improve product quality and availability for providers and patients.
Taxpayers and the federal budget bear lower federal revenue because the credits reduce corporate tax receipts, which could increase deficits or require spending cuts or offsets elsewhere.
Complex eligibility rules, caps (like the 50%‑of‑W‑2 cap), allocation tests, and qualification disputes will raise compliance costs for businesses and increase administrative and enforcement burdens for the IRS.
Benefits may concentrate with larger or otherwise better‑capitalized manufacturers (and some eligible firms), while smaller or foreign‑owned producers may be excluded, risking reduced competition and limited consumer price relief.
Based on analysis of 5 sections of legislative text.
Creates a 10.5% domestic medical manufacturing income credit and phased investment credits (up to 30%) for advanced equipment and EPA compliance property to spur U.S. production and investment.
Official title: Amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic manufacturing of critical medical supplies and drugs.
Introduced July 15, 2026 by Marsha Blackburn · Last progress July 15, 2026
Creates three new tax credits to encourage onshore production of drugs, biologics, medical devices, active pharmaceutical ingredients, and covered countermeasures and to speed investment in related equipment and pollution-control property. One credit (10.5%) targets qualifying domestic medical and drug manufacturing income; two investment credits (up to 30% initially) apply to advanced medical manufacturing equipment and to EPA compliance property that helps facilities meet air and water standards. Adds these credits into existing business- and investment-credit rules, adjusts anti‑avoidance provisions (BEAT and AMT interactions), sets phase‑down schedules for the investment credits through 2032, and requires annual reports from IRS, FDA, VA, and DOD on utilization and effects on domestic procurement and shortages.